Meinian Onehealth Healthcare Holdings (002044)
- 4.44
- -0.09-1.99%
Meinian Onehealth Healthcare Holdings (002044) News
Meinian Health (002044.SZ): Terminates the issuance of shares to purchase assets and related-party transaction matter, and withdraws application documents
Gelonghui, July 17 — Meinian Onehealth Healthcare (002044.SZ) announced that it originally intended to acquire, by issuing shares, 84.00% of the equity interest in Hengyang Meinian Onehealth Physical Examination Center Co., Ltd., 81.00% of Ningde Meinian Da Health Management Co., Ltd., 75.00% of Yantai Meinian Da Health Physical Examination Management Co., Ltd., 49.00% of Yantai Meinian Futian Health Physical Examination Management Co., Ltd., 52.81% of Wuhan Meici Aoya Technology Management Co., Ltd., 85.00% of Sanming Meinian Da Health Management Co., Ltd., and Feicheng Meinian Health Management Co., Ltd.
Meinian Health: 2026 Semi-Annual Performance Forecast
Afu-related stocks rallied collectively, with Meinian Health hitting the daily trading limit.
Gelonghui, July 10 | Stocks related to Ant Group's A Fu concept rose collectively today. Meinian Onehealth surged by the daily trading limit at one point, while Hanwei Technology climbed as much as 9.39%. As of 11:00 a.m., Meinian Onehealth was up 6.56%, Hanwei Technology gained 7.97%, WinHealth rose 6.06%, Keli Sensing increased by 3.61%, Lepu Medical advanced 2.65%, and Cofoe Medical, Yuwell Medical, Keep, Xiangshan Shares, and Yuwell Medical all posted gains. In news, Ant Group recently announced its investment in Bohe Health, becoming its largest external shareholder with a stake exceeding 28%. The two parties will collaborate on professional-grade AI health services centered around scenarios such as weight management.
Express News | AI healthcare stocks rebounded amid volatility, with Meinian Health and Neusoft Corporation both hitting the daily trading limit.
A-Share Market Close: STAR 50 Index Rises 3.84% to Hit Record High; Lab-Grown Diamonds and Semiconductor Sectors Surge
On June 18, China’s three major A-share indexes moved in mixed directions. As of market close, the Shanghai Composite Index declined by 0.43%, the Shenzhen Component Index rose by 0.94%, and the ChiNext Price Index surged 2.05% to a record high of 4,252 points. The STAR Market 50 Index climbed 3.84%, also reaching a new all-time high. Total market turnover amounted to RMB 3.33 trillion, with nearly 3,400 stocks ending lower. In market trading, the semiconductor sector strengthened amid volatility, led by gains in advanced packaging and HBM-related concepts; the CPO concept rallied, with Zhongji Xuchuang rising over 7% and its market capitalization surpassing that of Kweichow Moutai; rare earths and advanced metal materials sectors advanced, with companies such as Shenghe Resources, China Tungsten Hi-tech, and China Rare Earth Nonferrous Metals closing at their daily trading limits; CRO, MLCC, and Pei
Meinian AI Health Assistant "Jiankang Xiaomei" officially launches on mini-programs for both platforms, offering end-to-end services from health checkups to health management.
Recently, Meinian Group's AI health assistant "Jiankang Xiaomei" officially launched on the WeChat and Alipay mini-programs of Meinian Da Health. Leveraging Meinian Health's deep medical expertise and AI capabilities, Jiankang Xiaomei aims to address the common pain points users face after receiving their health check-up reports—namely, difficulty understanding, interpreting, and managing the results—by transforming complex medical data into clear, actionable guidance, thereby establishing a comprehensive service that spans from initial screening to long-term health management. Schematic illustration of the Meinian Da Health WeChat/Alipay dual-platform mini-programs. Currently, China has over 300 million patients with chronic diseases and conducts more than 500 million health screenings annually, reflecting continuously rising demand for health management services. However, traditional health screening services often stop short at "issuing reports"
Meinian Onehealth to Pay Deposit for Bangjie's Capital Reserves
A-Share Market Movement | Meinian Health Drops Nearly 4% as Shareholder Plans to Sell Up to 3% Stake, Facing Pressure After Yesterday’s Surge of Over 7%
Gelonghui, May 29 | Meinian Health (002044.SZ), which surged more than 7% yesterday, retreated nearly 4% to close at RMB 5.67, giving it a total market capitalization of RMB 22.19 billion. According to an announcement, Meinian Health disclosed a share reduction plan, stating that shareholder Hangzhou Haoyue Enterprise Management Co., Ltd. intends to sell no more than 117.4276 million shares, representing up to 3% of the company’s total share capital. Additionally, it is reported that the company has issued two such share reduction announcements over the past three years. It should be noted that the number of shares indicated for potential reduction in the announcement does not necessarily reflect the final actual number of shares sold.
Molybdenum industry leader clarifies after two daily trading limits in three days: rumors about chip suppliers and large orders are unfounded | Selected Post-Market Announcements
The global molybdenum industry leader has issued a trading risk warning; 'the first mattress stock' announced a major litigation notice; and this brain-computer interface concept stock received an administrative regulatory measures decision letter...
Express News | Meinian Health: Shareholder Hangzhou Haoyue plans to reduce its stake by no more than 3% of the company's shares.
Meinian Health (002044): Q1 Revenue Under Short-Term Pressure; Deepening AI Strategy Expected to Support Performance Improvement
Key View: The company's 2025 performance met expectations. Revenue in Q1 2026 was slightly below expectations, while profit was in line with expectations. The company's Q1 2026 revenue faced short-term pressure due to the Lunar New Year seasonal slowdown, but the loss narrowed year-over-year through further cost reduction and efficiency enhancement measures.
Stock Movement | Baize Medical (02609) Rises Over 4% as Subsidiary Signs Strategic Cooperation Agreement with Meinian Onehealth to Strengthen Implementation of H@H Service Model
Baize Medical (02609) surged over 4% during the trading session. As of the time of writing, it was up 2.1%, trading at HKD 5.35, with a turnover of HKD 42.315 million.
When Prevention Meets Specialization! Baize Medical Partners with Meinian Onehealth to Launch a New Chapter in Full-Cycle Tumor Management
In May 2026, China's health management industry witnessed a landmark collaboration – Bai Ze Medical Group (02609.HK) and Meinian Onehealth Healthcare Holdings Co., Ltd. (002044.SZ, referred to as "Meinian Onehealth") officially signed a strategic cooperation agreement, announcing their joint effort to establish a full-cycle health management system integrating "screening-diagnosis-treatment-rehabilitation" on a nationwide scale. This collaboration is not merely a simple exchange of customer referrals, nor a traditional channel partnership; instead, it represents a systematic reconfiguration focused on "shifting the focus of medical care forward" and "extending the service chain." It signifies a pivotal development in China's healthcare sector.
Bayzed Health Forms Strategic Alliance With Meinian to Build Full-Cycle Health Management Network
Baize Medical (02609) subsidiary signs strategic cooperation agreement with Meinian Onehealth Healthcare
Baize Medical (02609) announced that on May 18, 2026, its wholly-owned subsidiary, Baize Medical Investment Group Co., Ltd., entered into a strategic cooperation agreement with Meinian Onehealth Healthcare Holdings Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 002044.SZ), through its subsidiary, Meinian Onehealth Healthcare (Group) Co., Ltd. (Meinian Onehealth). Both parties will leverage their respective advantageous resources to jointly promote the establishment of an integrated, full-cycle health management service system encompassing 'prevention-screening, diagnosis and treatment, and rehabilitation' on a nationwide scale.
In-depth Report on Meinian Health (002044): AI-Driven Upgrade in Health Management Demonstrates Significant Long-Term Value
The demand for preventive health management is driving the medical examination industry to shift from "optional consumption" to "preventive necessity." According to data from the National Bureau of Statistics, by 2025, the population aged 60 and above in China will account for 23%, with aging and the high incidence of chronic diseases leading to more frequent
Meinian Health (002044) 2025 Annual Report & 2026 Q1 Report Commentary: AI-related Revenue Achieves High Growth, Profitability Continues to Improve
Key investment highlights: In 2025, the company achieved total operating revenue of 10.36 billion yuan (-3.20%, indicating year-on-year growth rate, hereinafter the same), net profit attributable to shareholders of 285 million yuan (+1.09%), and non-recurring net profit attributable to shareholders of 2...
Research Report Insights | Huaan Securities: Reiterates 'Buy' Rating for Meinian Health, Significant Growth in AI-Related Revenue
Gelonghui May 7 | A research report by Huaan Securities pointed out that Meinian Health faced short-term seasonal pressure in Q1 of 2026, while its AI-related revenue saw significant growth. In the fiscal year 2025, the company achieved total operating revenue of 10.36 billion yuan (a year-on-year decrease of 3.20%) and net profit attributable to shareholders of 285 million yuan (a year-on-year increase of 1.09%). In the first quarter of 2026, the net profit attributable to shareholders was -255 million yuan (a year-on-year increase of 7.37%, achieving a reduction in losses). The company has made remarkable progress in cost reduction and efficiency enhancement, and its group and individual examination model has gradually proven effective. Meinian Health's revenue in the first quarter of 2026 declined year-on-year, mainly due to short-term pressure caused by seasonal factors. As of the Q1 2026 earnings report period.
Meinian Health (002044) 2025 Annual Report and 2026 Q1 Earnings Commentary: Profit Resilience Highlighted, AI Empowerment Demonstrates Results
Event: On April 30, 2026, the company released its annual report for 2025 and first-quarter results for 2026. In 2025, the company achieved operating revenue of 10.36 billion yuan, a year-on-year decrease of 3.20%; net profit attributable to shareholders was 285 million yuan.
Meinian Health: First Quarter Report for 2026